Published in Clin Infect Dis on February 15, 2010
Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks. AIDS Res Hum Retroviruses (2010) 1.03
Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. J Acquir Immune Defic Syndr (2011) 0.97
Sex differences in HIV outcomes in the highly active antiretroviral therapy era: a systematic review. AIDS Res Hum Retroviruses (2014) 0.88
Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infection. AIDS Res Hum Retroviruses (2012) 0.86
Long-term albendazole effectiveness for hepatic cystic echinococcosis. Am J Trop Med Hyg (2011) 0.79
Promoting early presentation of breast cancer in older women: implementing an evidence-based intervention in routine clinical practice. J Cancer Epidemiol (2012) 0.75
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Attitudes and beliefs of African Americans toward participation in medical research. J Gen Intern Med (1999) 11.58
Are racial and ethnic minorities less willing to participate in health research? PLoS Med (2005) 7.88
The Tuskegee Syphilis Study, 1932 to 1972: implications for HIV education and AIDS risk education programs in the black community. Am J Public Health (1991) 7.73
The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med (1998) 6.26
Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med (2002) 5.52
African Americans' views on research and the Tuskegee Syphilis Study. Soc Sci Med (2001) 5.23
Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med (1999) 5.05
Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis (2009) 4.96
The effectiveness of psychotherapy. The Consumer Reports study. Am Psychol (1995) 4.49
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA (2006) 3.23
Factors affecting African-American participation in AIDS research. J Acquir Immune Defic Syndr (2000) 2.96
Racial disparities in HIV virologic failure: do missed visits matter? J Acquir Immune Defic Syndr (2009) 2.58
Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med (2000) 2.49
The challenge of minority recruitment in clinical trials for AIDS. JAMA (1992) 2.47
External validity of clinical trials in acute myocardial infarction. Arch Intern Med (2007) 2.14
Race, gender, drug use, and participation in AIDS clinical trials. Lessons from a municipal hospital cohort. J Gen Intern Med (1997) 2.00
The relationship of disease severity, health beliefs and medication adherence among HIV patients. AIDS Care (2000) 1.81
The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 1.72
Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil. J Acquir Immune Defic Syndr (2005) 1.69
A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis (2003) 1.59
Duration of highly active antiretroviral therapy regimens. Clin Infect Dis (2003) 1.50
Race and mental health diagnosis are risk factors for highly active antiretroviral therapy failure in a military cohort despite equal access to care. J Acquir Immune Defic Syndr (2007) 1.46
Do blacks believe that HIV/AIDS is a government conspiracy against them? Prev Med (1999) 1.40
Principles of effectiveness trials and their implementation in VA Cooperative Study #430: 'Reducing the efficacy-effectiveness gap in bipolar disorder'. J Affect Disord (2001) 1.22
Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. AIDS Res Hum Retroviruses (1999) 1.22
Efficacy vs effectiveness trial results of an indicated "model" substance abuse program: implications for public health. Am J Public Health (2006) 1.21
Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. Eur Heart J (2006) 1.18
Participation in clinical trials among women living with HIV in Canada. Canadian Women's HIV Study Group. CMAJ (1998) 1.14
Research on psychotherapy efficacy and effectiveness: between Scylla and Charybdis? Psychol Bull (2000) 1.13
HIV-infected African Americans are willing to participate in HIV treatment trials. J Gen Intern Med (2007) 1.11
Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry. Am Heart J (2003) 1.03
Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag (2008) 0.97
Unmeasured confounding caused slightly better response to HAART within than outside a randomized controlled trial. J Clin Epidemiol (2007) 0.94
Participation in clinical studies among patients infected with HIV-1 in a single treatment centre over 12 years. HIV Med (2000) 0.91
Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy. Eur J Med Res (2003) 0.87
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA (2006) 17.93
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91
Years of life lost due to obesity. JAMA (2003) 12.18
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum (2008) 9.94
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49
Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med (2012) 7.04
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis (2009) 4.96
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med (2005) 4.83
Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med (2005) 4.68
Culturally appropriate storytelling to improve blood pressure: a randomized trial. Ann Intern Med (2011) 4.24
The therapeutic implications of timely linkage and early retention in HIV care. AIDS Patient Care STDS (2009) 3.78
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis (2006) 3.72
Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med (2004) 3.48
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum (2007) 3.38
Disparities in use of a personal health record in a managed care organization. J Am Med Inform Assoc (2009) 3.26
Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol (2008) 3.14
Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. Arch Intern Med (2008) 2.99
Patient complexity: more than comorbidity. the vector model of complexity. J Gen Intern Med (2007) 2.91
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses (2002) 2.89
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Early retention in HIV care and viral load suppression: implications for a test and treat approach to HIV prevention. J Acquir Immune Defic Syndr (2012) 2.74
Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis (2014) 2.65
Racial disparities in HIV virologic failure: do missed visits matter? J Acquir Immune Defic Syndr (2009) 2.58
Health care system and policy factors influencing engagement in HIV medical care: piecing together the fragments of a fractured health care delivery system. Clin Infect Dis (2011) 2.57
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
Measuring retention in HIV care: the elusive gold standard. J Acquir Immune Defic Syndr (2012) 2.47
Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis (2004) 2.42
Beyond joint implant registries: a patient-centered research consortium for comparative effectiveness in total joint replacement. JAMA (2012) 2.37
Failure to establish HIV care: characterizing the "no show" phenomenon. Clin Infect Dis (2007) 2.37
Users of Internet health information: differences by health status. J Med Internet Res (2003) 2.35
Modeling sequence evolution in acute HIV-1 infection. J Theor Biol (2009) 2.32
Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 2.29
Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia. Int J Epidemiol (2009) 2.25
Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. J Clin Epidemiol (2008) 2.25
Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia. AIDS (2008) 2.21
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18
Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med (2011) 2.17
The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African Americans through European genetic admixture. Arthritis Rheum (2008) 2.13
Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS (2008) 2.13
Pharmaceuticals companies' medication assistance programs: potentially useful but too burdensome to use? South Med J (2009) 2.08
Survival advantage of black patients with kidney disease after acute myocardial infarction. Clin J Am Soc Nephrol (2006) 2.08
Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings? Clin Infect Dis (2006) 2.07
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05
Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis (2011) 2.02
Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department. Hepatology (2015) 1.99
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr (2002) 1.98
Transmission of HIV-1 and HLA-B allele-sharing within serodiscordant heterosexual Zambian couples. Lancet (2004) 1.97
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
Atypical presentations among Medicare beneficiaries with unstable angina pectoris. Am J Cardiol (2002) 1.92
Racial disparities in coronary heart disease: a sociological view of the medical literature on physician bias. Ethn Dis (2004) 1.92
Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. Clin Infect Dis (2011) 1.91
Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med (2015) 1.86
Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum (2006) 1.85
Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy. AIDS Res Hum Retroviruses (2008) 1.84
Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis (2010) 1.84
An empirical approach to defining loss to follow-up among patients enrolled in antiretroviral treatment programs. Am J Epidemiol (2010) 1.81
Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J Infect Dis (2010) 1.79
MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis (2014) 1.78
Quality of care indicators for gout management. Arthritis Rheum (2004) 1.77
Reasons for not intensifying medications: differentiating "clinical inertia" from appropriate care. J Gen Intern Med (2007) 1.77
Nurse staffing and mortality for Medicare patients with acute myocardial infarction. Med Care (2004) 1.77
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis (2011) 1.77
Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr (2013) 1.72
The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 1.72
Relation of lifetime trauma and depressive symptoms to mortality in HIV. Am J Psychiatry (2007) 1.68
A systematic review and meta-regression of temporal trends in adult CD4(+) cell count at presentation to HIV care, 1992-2011. Clin Infect Dis (2013) 1.67
Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users. Pharmacoepidemiol Drug Saf (2006) 1.65